Data from Pharmawand - Curated by EPG Health - Date added 11 December 2018
Long-term outcomes data from a large population-based study further support the utility of the Oncotype DX Breast Recurrence Score test, from Genomic Health, to optimise chemotherapy recommendations in patients with early-stage, hormone-receptor positive, HER2-negative breast cancer with or without lymph node involvement. Real-world evidence from a more than 80,000 patient study, based on an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) registry programme of the National Cancer Institute (NCI), confirmed that the Oncotype DX Breast Recurrence Score result is predictive of chemotherapy benefit in patients with node-negative disease (p=0.009), with no chemotherapy benefit with Recurrence Score results less than 26.
In patients with node-negative disease and Recurrence Score results less than 26 not treated with chemotherapy, the Breast Cancer Specific Survival (BCSS) was greater than 96 percent at nine years. In patients with node-positive disease not treated with chemotherapy and Recurrence Score results less than 18, BCSS was greater than 97 percent at nine years.
Comment: Importantly, the new real-world evidence reinforces the paradigm established by the TAILORx study, which provided definitive information on how to treat women with node-negative early-stage breast cancer based on their Oncotype DX Breast Recurrence Score results. TAILORx - the largest randomised adjuvant breast cancer treatment trial ever conducted - identified the vast majority of women (Recurrence Score result up to 25) who receive no substantial benefit from chemotherapy, as well as the important minority (Recurrence Score result 26-100) for whom chemotherapy can be life-saving. Thus, the Oncotype DX test can greatly reduce both over- and undertreatment with chemotherapy. Data were presented at the 2018 San Antonio Breast Cancer Symposium (SABCS).